New insights into the pathophysiology and management of bone disease in multiple myeloma

Br J Haematol. 2003 Dec;123(5):758-69. doi: 10.1046/j.1365-2141.2003.04712.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Bone Diseases / drug therapy
  • Bone Diseases / etiology*
  • Bone Diseases / metabolism
  • Bone Resorption
  • Carrier Proteins / metabolism
  • Chemokine CCL4
  • Cytokines / metabolism
  • Diphosphonates / therapeutic use
  • Glycoproteins / metabolism
  • Humans
  • Macrophage Inflammatory Proteins / metabolism
  • Membrane Glycoproteins / metabolism
  • Multiple Myeloma / complications*
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / metabolism
  • Osteoprotegerin
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • Receptors, Cytoplasmic and Nuclear / metabolism
  • Receptors, Tumor Necrosis Factor

Substances

  • Carrier Proteins
  • Chemokine CCL4
  • Cytokines
  • Diphosphonates
  • Glycoproteins
  • Macrophage Inflammatory Proteins
  • Membrane Glycoproteins
  • Osteoprotegerin
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • Receptors, Cytoplasmic and Nuclear
  • Receptors, Tumor Necrosis Factor
  • TNFRSF11A protein, human
  • TNFRSF11B protein, human
  • TNFSF11 protein, human